Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer

The recent manuscript in New England Journal of Medicine by Antonarakis et al.1 has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, Dong, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Invited Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430945/
https://www.ncbi.nlm.nih.gov/pubmed/25532583
http://dx.doi.org/10.4103/1008-682X.145069
Descripción
Sumario:The recent manuscript in New England Journal of Medicine by Antonarakis et al.1 has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses. Further, the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3–1.4 months in AR-V7-positive patients as compared to 5.3–6.1 months in AR-V7 negative patients. AR-V7 in CTCs was also associated with shorter survival.

Ejemplares similares